Genmab A (GMAB) Income towards Parent Company (2018 - 2026)
Genmab A (GMAB) reported Income towards Parent Company of $74.0 million for Q1 2026, down 69.67% on a YoY basis from $244.0 million in Q1 2025, and down 84.65% quarter-over-quarter from $482.0 million in Q3 2025.
Genmab A (GMAB) Income towards Parent Company (2018 - 2026) Analysis & Trends
Genmab A has reported Income towards Parent Company for 6 years, with the latest figure at $74.0 million in Q1 2026.
- For the quarter ending Q1 2026, Income towards Parent Company fell 69.67% year-over-year to $74.0 million; the trailing twelve-month figure through Mar 2026 stood at $979.0 million (up 21.77% YoY), and the FY2025 full-year result was $963.0 million, down 15.0% from the prior year.
- Income towards Parent Company for Q1 2026 stood at $74.0 million, down from $482.0 million in the prior quarter.
- The five-year high for Income towards Parent Company was $482.0 million in Q3 2025, with the low at $74.0 million in Q1 2026.
- Historically, Income towards Parent Company has averaged $290.3 million across 3 years, with a median of $253.0 million in 2024.
- Annual changes were most pronounced in 2025 — Income towards Parent Company jumped 90.51% — and 2026, when it sank 69.67%.
- Genmab A's Income towards Parent Company stood at $253.0 million in 2024, then soared by 90.51% to $482.0 million in 2025, then plunged by 84.65% to $74.0 million in 2026.
- The last three Income towards Parent Company figures came in at $74.0 million (Q1 2026), $482.0 million (Q3 2025), and $423.0 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Genmab A | 48.57 Bn | 47.05 Bn | 831.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 74.00 Mn |
| Sep 30, 2025 | 482.00 Mn |
| Jun 30, 2025 | 423.00 Mn |
| Mar 31, 2025 | 244.00 Mn |
| Sep 30, 2024 | 253.00 Mn |
| Jun 30, 2024 | 307.00 Mn |
| Mar 31, 2024 | 249.00 Mn |
| Sep 30, 2020 | 671.00 |
| Dec 31, 2019 | 699.00 |
| Sep 30, 2019 | 699.28 Mn |
| Dec 31, 2018 | 230.60 Mn |